Cariprazine

Brand Names: VRAYLAR, Ryeagila

Drug Class: Atypical antipsychotic / Dopamine-serotonin system modulator

Overview

Cariprazine is an atypical antipsychotic used for schizophrenia, bipolar disorder, and as adjunctive treatment for major depressive disorder. It functions as a partial agonist at dopamine D2/D3 receptors and serotonin 5-HT1A receptors with antagonist activity at other serotonin receptors. The medication requires careful titration and monitoring for metabolic, neurological, and cardiovascular effects.

Mechanism of Action

Cariprazine acts as a partial agonist at dopamine D2 and D3 receptors with high binding affinity, and at serotonin 5-HT1A receptors. It functions as an antagonist at 5-HT2B and 5-HT2A receptors with moderate to high affinity, and binds to histamine H1 receptors. This multimodal receptor profile contributes to its antipsychotic, mood-stabilizing, and antidepressant effects.

Indications

  • Treatment of schizophrenia in adult and pediatric patients 13 years and older
  • Acute treatment of manic or mixed episodes associated with bipolar I disorder in adult and pediatric patients 10 years and older
  • Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adult patients
  • Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adult patients

Common Doses

  • 1.5 mg
  • 3 mg
  • 4.5 mg
  • 6 mg

Dosage

Initial dose typically 1.5 mg daily, titrated based on indication and tolerability. Maximum recommended dose is 6 mg daily. Requires gradual titration with dose adjustments based on clinical response and tolerability.

Contraindications

  • History of hypersensitivity reaction to cariprazine (rash, pruritus, urticaria, angioedema)

Side Effects

  • Extrapyramidal symptoms
  • Akathisia
  • Weight gain
  • Sedation/somnolence
  • Insomnia
  • Nausea
  • Constipation
  • Dyspepsia
  • Increased appetite
  • Anxiety
  • Restlessness
  • Dizziness
  • Orthostatic hypotension
  • Metabolic changes
  • Tardive dyskinesia
  • Neuroleptic malignant syndrome

Interactions

  • Strong or moderate CYP3A4 inhibitors: Increase cariprazine exposure - requires dosage reduction
  • CYP3A4 inducers: Not recommended due to unpredictable effects on active metabolites

Counseling Points

  • Take consistently with or without food
  • Report any signs of infection, fever, or sore throat immediately
  • Monitor for mood changes, suicidal thoughts, or unusual behaviors
  • Be aware of potential sedation and avoid driving until effects known
  • Report any involuntary movements, muscle stiffness, or fever
  • Regular monitoring of weight, blood glucose, and lipids recommended
  • Avoid sudden position changes to prevent dizziness
  • Inform all healthcare providers about all medications being taken